Literature DB >> 22640036

Controlled and continuous release ocular drug delivery systems: pros and cons.

Hamdy Abdelkader1, Raid G Alany.   

Abstract

Topical ocular drug administration is the most preferred route for treating conditions affecting the surface of the eye as well as anterior segment diseases; this is mainly due to the rapid and localised drug action and patient acceptability. However, the ocular bioavailability is typically less than 5% from conventional ophthalmic dosage forms such as eye drops. This is mainly due to the unique anatomical and physiological features of the eye. One of the effective pharmaceutical approaches is to provide a controlled and continuous drug release to the surface of the eye to compensate drug loss by nasolacrimal drainage and non-productive absorption of the topically applied drug. This review provides a critical appraisal (advantages and drawbacks) of the different drug delivery strategies that provides controlled and continuous drug supply to the surface of the eye; it covers research conducted over the past three decades.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640036     DOI: 10.2174/156720112801323125

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  11 in total

Review 1.  A New Vision for the Eye: Unmet Ocular Drug Delivery Needs.

Authors:  Hongwen M Rivers; Siladitya Ray Chaudhuri; Jaymin C Shah; Sachin Mittal
Journal:  Pharm Res       Date:  2015-06-09       Impact factor: 4.200

2.  Investigation into the Emerging Role of the Basic Amino Acid L-Lysine in Enhancing Solubility and Permeability of BCS Class II and BCS Class IV Drugs.

Authors:  Hamdy Abdelkader; Zeinab Fathalla
Journal:  Pharm Res       Date:  2018-06-18       Impact factor: 4.200

3.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

Review 4.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

Review 5.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

Review 6.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

Review 7.  Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.

Authors:  Philippe Daull; Frédéric Lallemand; Jean-Sébastien Garrigue
Journal:  J Pharm Pharmacol       Date:  2014-04       Impact factor: 3.765

8.  The suprachoroidal space: from potential space to a space with potential.

Authors:  Elad Moisseiev; Anat Loewenstein; Glenn Yiu
Journal:  Clin Ophthalmol       Date:  2016-01-25

9.  Opportunities and obstacles to the development of nanopharmaceuticals for human use.

Authors:  Nasser Nassiri Koopaei; Mohammad Abdollahi
Journal:  Daru       Date:  2016-10-06       Impact factor: 3.117

10.  On the Anticataractogenic Effects of L-Carnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor?

Authors:  Hamdy Abdelkader; Michael Longman; Raid G Alany; Barbara Pierscionek
Journal:  Oxid Med Cell Longev       Date:  2016-10-16       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.